| 28th May 2015
Recent research from the World Health Organisation and the Mayo Clinic on the impact of (and influences on) a patient’s ability to adhere to their treatment regime has shown that an astounding amount of patients do not follow or complete their treatment as prescribed.
In part one of this series, Elisa del Galdo looked at the complex factors around patient non-adherence. In the final instalment, she examines additional barriers to adherence as well as the patient persona most likely to not adhere to their treatment plan.
Efficacy in drugs is demonstrated via tightly controlled and monitored clinical trials. In the real world, the same drugs may not be as effective; not because they no longer work, but because patients very often do not take their treatments as prescribed. Research by the NIH has shown that 25%-78% of patients do not adhere to their prescribed treatment. For Pharma, addressing the issue of non-adherence is complex.
Ideally, healthcare professionals (HCPs) will take a more holistic approach when deciding on a treatment for their patient, rather than relying on efficacy data. However, some key questions are raised in the process of choosing the treatment:
There are many variables to consider; some of the information available to a patient might be conflicting, which causes further confusion when making a decision about the best treatment option. For example, drugs that show superior efficacy in clinical trials, where adherence is tightly controlled, may not show the same level of efficacy in a situation where the patient has the majority of the responsibility for adherence. The HCP has to determine whether this is due to non-adherence, or to an underlying effect in a real-world scenario. This could include:
The solution isn't just about communicating the benefits of adherence – most physicians will understand and completely agree that adherence is vital, as without it, achieving the desired outcomes for your patients is incredibly difficult; patients tend to echo this sentiment.
A ‘one size fits all’ approach will be ineffective at targeting all the factors that influence each patient. Providing additional services, guidance, advice, and tools to influence and support the desired behaviour, which is likely to require a change of habits or behaviour change, will help to ensure patients understand:
By going ‘beyond the pill’ with the support of Pharma, the healthcare system, and HCPs, an environment and tools can be created for the patient that will help them overcome the barriers to adherence they experience, and result in better outcomes.
During our research with oncology and diabetes patients, we documented the patient journey in a number of stages from pre-diagnosis of their condition to diagnosis and treatment, followed by either remission, recovery or a maintenance phase. Throughout this journey, patients all followed a similar path, until they got to the final stage – recovery/maintenance. It seemed to be at this point that patients split into three different personas:
The advocate – these patients are highly knowledgeable on most aspects of their condition and the treatment options available. They tend to become advocates, or what we refer to as a Patient Key Opinion Leaders (PKOLs) and often influence other patients via support groups or even creating charities.
The self-concerned – these patients are similar to the advocates in their knowledge, however they tend to focus this knowledge on their own wellbeing (and the benefit it has for their family members) rather than for a community of similar patients.
The unengaged – these patients find it difficult to engage with their HCPs and their treatment. They have not gained enough understanding of their condition or treatment to move past their rationalisation of non-adherence.
Although we can’t predict the percentages of patients in each group, based on other research in the field and our experience at Blue Latitude Health, it is the unengaged who are most likely to represent the 50% of the patient population that does not adhere to their treatment regime. In contrast, the advocate is likely to be a very small percentage, perhaps less than 5%.
The approach is two-fold:
Only by clearly understanding the patient’s barriers to adherence to their treatment will we be able to create solutions that truly work within the context in which the patient exists. Ultimately, pharma companies want their product to be successful in treatment, and to be the most prescribed. HCPs are focused on treating their patients for the best possible outcomes, and patients want to be well. With the design and delivery of research-based, insight-driven innovative solutions, the best possible outcomes can be achieved.
| 12th April 2017
Cultural context is everything when you’re working with teams from a different background to your own. Senior Associate UX Researcher Dorottya Okros talks through the common communication and negotiation pitfalls of working with Eastern Europe and the CIS for British presenters.
| 5th April 2017
Channel strategy has long been a hot topic for pharma and is often regarded as the answer to many of today’s marketing challenges. Head of Brand Strategy Jenna Earl discusses these challenges faced by pharmaceutical marketers today, and if channel disruption is really the answer.
| 29th March 2017
Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.